The FDA issued 30 warning letters to telehealth companies for making false and misleading claims about compounded GLP-1 receptor agonists, targeting marketing that implied equivalence to FDA-approved formulations.

This enforcement action addresses a critical gap in telehealth oversight. Compounded GLP-1 products (used for weight loss and diabetes management) have proliferated through direct-to-consumer telehealth platforms, often marketed as equivalent to Ozempic, Wegovy, or Mounjaro without clinical evidence supporting purity, potency, or bioavailability. The FDA's action targets specific false claims—particularly that compounded versions are "the same" as approved drugs or equally effective. This matters because compounded GLP-1s operate outside standard manufacturing controls, creating patient safety risks and driving CMS and private insurers to tighten coverage policies. The warning letters serve as regulatory notice but carry no immediate financial penalties unless companies fail to comply within 15 days.

For medical practices, DSOs, and specialty groups, this enforcement signals tightening scrutiny of telehealth marketing and compounded drug claims. Practices referring patients to or partnering with telehealth platforms offering compounded GLP-1s face reputational and liability risk if those platforms continue non-compliant marketing. More immediately, expect private insurers and CMS to cite FDA enforcement in coverage denials for compounded GLP-1s, shifting patient demand back toward FDA-approved formulations—affecting practice revenue from weight-loss and diabetes programs. Practices should audit any telehealth partnerships and ensure marketing claims align with FDA guidance on compounded medications.

What to watch: FDA compliance responses from the 30 firms within 15 days and follow-up enforcement actions if warning letters are ignored.